Table 1.
Summary of clinical and pathological data of human individuals used to assess the performance of the quartet test (n = 146)
| Number | Gender | |||
|---|---|---|---|---|
| Urine samples | of samples | F | M | Mean age ± STDEV |
| Control samples | 48 | 22 | 26 | 60.70 ± 11.12 |
| Healthy individuals | 18 | 9 | 9 | 59.17 ± 10.14 |
| Benign disorders | 30 | 13 | 17 | 61.62 ± 11.74 |
| Hematuria | 2 | 2 | 0 | 44.34 ± 3.51 |
| Elevated PSA | 2 | 0 | 2 | 74.08 ± 8.66 |
| Hyperlipidemia/hypercholesterolemia | 7 | 1 | 6 | 66.52 ± 9.35 |
| Kidney stone | 1 | 0 | 1 | 55.31 |
| Renal failure | 1 | 0 | 1 | 67.96 |
| Stricture of ureter | 1 | 0 | 1 | 46.39 |
| Neurogenic bladder | 3 | 3 | 0 | 50.35 ± 7.95 |
| Others | 13 | 7 | 6 | 65.96 ± 9.24 |
| Tumor samples | 98 | 23 | 75 | 66.00 ± 12.56 |
| LGPUC (Ta–T1a) | 56 | 16 | 40 | 64.48 ± 12.57 |
| HGUC (T1b–higher) | 42 | 7 | 35 | 68.01 ± 12.41 |
| Total | 146 | 45 | 101 | 64.26 ± 12.32 |
F = female; HGUC = high-grade urothelial carcinoma; LGPUC = low-grade papillary urothelial carcinoma; M = male; PSA = prostate-specific antigen; STDEV = standard deviation.